Eugene A. Bauer Sells 3,000 Shares of Dermira Inc (DERM) Stock

Dermira Inc (NASDAQ:DERM) insider Eugene A. Bauer sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $27.34, for a total transaction of $82,020.00. The sale was disclosed in a filing with the SEC, which is available through this link.

Shares of Dermira Inc (NASDAQ DERM) opened at $26.70 on Friday. Dermira Inc has a fifty-two week low of $21.35 and a fifty-two week high of $38.75. The company has a debt-to-equity ratio of 1.40, a current ratio of 4.68 and a quick ratio of 4.68. The stock has a market cap of $1,110.00, a P/E ratio of -4.29 and a beta of 0.80.

Several equities research analysts recently weighed in on DERM shares. Needham & Company LLC reissued a “buy” rating and set a $46.00 price target on shares of Dermira in a research report on Sunday, September 17th. Cantor Fitzgerald restated a “buy” rating and issued a $45.00 target price on shares of Dermira in a report on Tuesday, September 26th. Leerink Swann restated an “outperform” rating and issued a $41.00 target price (down previously from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Zacks Investment Research cut shares of Dermira from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Finally, BidaskClub upgraded shares of Dermira from a “sell” rating to a “hold” rating in a report on Saturday, December 2nd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $41.00.

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its stake in shares of Dermira by 15.6% during the 2nd quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock worth $114,294,000 after acquiring an additional 529,405 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Dermira by 0.3% during the 3rd quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock worth $71,300,000 after acquiring an additional 7,746 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Dermira by 9.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock worth $40,735,000 after acquiring an additional 125,157 shares during the last quarter. Voya Investment Management LLC boosted its stake in shares of Dermira by 61.4% during the 2nd quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock worth $35,783,000 after acquiring an additional 467,356 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Dermira by 38.4% during the 2nd quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock worth $23,946,000 after acquiring an additional 228,093 shares during the last quarter. Institutional investors own 99.47% of the company’s stock.

WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/12/dermira-inc-derm-insider-eugene-a-bauer-sells-3000-shares.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply